News and Events Day: April 17, 2019

In the last several months, SKBP has achieved several remarkable drug development milestones, including the first FDA approval of an SKBP-discovered drug (Sunosi™, for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea, which has been licensed to Jazz Pharmaceuticals) and FDA acceptance of their NDA submission for cenobamate, an investigational antiepileptic drug.